Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12625000130460
Ethics application status
Approved
Date submitted
13/12/2024
Date registered
5/02/2025
Date last updated
5/02/2025
Date data sharing statement initially provided
5/02/2025
Type of registration
Prospectively registered
Titles & IDs
Public title
Continuous monitoring of Intensive Care Unit (ICU) patients’ vancomycin levels in interstitial fluid: a pilot feasibility study of a new device
Query!
Scientific title
Continuous monitoring of Intensive Care Unit (ICU) adult patients’ vancomycin levels in interstitial fluid: a pilot feasibility study of a new device
Query!
Secondary ID [1]
313571
0
Nil Known
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Infection
336089
0
Query!
Condition category
Condition code
Infection
332647
332647
0
0
Query!
Studies of infection and infectious agents
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Part 1: Adults in ICU prescribed vancomycin will be invited to participate in the study. Participants can be enrolled if their guardian provides consent prior to applying the device. These participants will be approached at a later stage to obtain consent to continue to participate in the study. Consenting participants will have the device applied to the skin (e.g. upper arm) as soon as feasible upon commencing the course of vancomycin. This device will remain in place for 24 hours. A second device will be applied to the skin (e.g. upper arm) 11-12 hours after application of the first device. The second device will remain in place for 12 hours. Both devices are the same Nutromics Sensor Device, meaning, two of the same Nutromics Sensor Device will be applied, one for 24 hours and the other for 12 hours. Photographs will be taken pre and post Device application to assess for adverse events. This process will be repeated on a second occasion.
Participants with Intermittent Vancomycin Dosing Regimens:
Blood samples (4 mL) will be collected during a dosing interval. Blood samples for the measurement of plasma vancomycin concentration will be collected prior to the administration of the vancomycin infusion in each 24 hour observation period, at the end of the infusion and then at 1, 2, 3, 4, 6, 8 and 10-hours post-the end of each infusion. In addition, any vancomycin concentrations obtained as part of standard care will be recorded. Inflammatory markers (e.g. CRP) will also be tested at the 1 and 10 hour time points for each 24 hour observation period. This blood sampling schedule will be repeated on a second occasion in conjunction with the application of the devices.
Participants with Continuous Vancomycin Dosing Regimens:
Blood samples (4 mL) will be collected during a continuous infusion. Blood samples for the measurement of plasma vancomycin concentration will be collected 2 hours after the syringe/infusion swap and 2 hours prior to the next syringe/infusion swap. In addition, any vancomycin concentrations obtained as part of standard care will be recorded. Inflammatory markers (e.g. CRP) will also be tested at these time points for each 24-hour observation period. This blood sampling schedule will be repeated on a second occasion in conjunction with the application of the devices.
The first Nutromics Sensor Device applied to the patient in the 24 hour observational period will remain on the upper arm of the patient for 24 hours, and the second Device applied 12 hours into the period of observation will remain applied for 12 hours. The Devices are single use, to be applied by a healthcare professional, and have been shown to be relatively painless and have no impact on mobility. Participating in this study will have no impact on their prescribed care or vancomycin therapy.
Part 2: After having provided written informed consent an in-depth survey will be conducted with healthcare professionals, including prescribers, nurses and pharmacists, involved in using the device (Part 1) to better understand feasibility, potential utility and impact on practice. Survey questions will focus on current practice and their role in using the device during Part 1. Participants will be asked to comment on the process (feasibility) of integrating the device into routine critical care medicine and any suggestions for improvements.
Query!
Intervention code [1]
330167
0
Treatment: Devices
Query!
Comparator / control treatment
Standard care - blood sampling to determine vancomycin concentration.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
340146
0
Determination of interstitial fluid vancomycin concentrations
Query!
Assessment method [1]
340146
0
Nutromics Sensor Device data analysis.
Query!
Timepoint [1]
340146
0
Continuous monitoring for each 24-hour observation period.
Query!
Primary outcome [2]
340372
0
Determination of plasma vancomycin concentrations
Query!
Assessment method [2]
340372
0
Immunoassay analysis of blood samples
Query!
Timepoint [2]
340372
0
Blood is taken: - prior to the administration of each vancomycin infusion, then at the end of the infusion and then at 1, 2, 3, 4, 6, 8 and 10-hours post-end of the infusion (if patient on intermittent vancomycin regimen), OR - 2 hours after the syringe/infusion swap and 2 hours prior then next syringe/infusion swap (if patient on continuous vancomycin therapy).
Query!
Secondary outcome [1]
442980
0
Efficacy of vancomycin treatment
Query!
Assessment method [1]
442980
0
The following data will be collected from electronic medical records to assess efficacy of vancomycin treatment: - Treatment duration - ICU length of stay - hospital length of stay - re-admission This is a composite outcome.
Query!
Timepoint [1]
442980
0
30 days post cessation of the course of therapy.
Query!
Secondary outcome [2]
442981
0
To characterise the safety of the Device, including adverse events, used to determine interstitial fluid concentrations of vancomycin in ICU participants.
Query!
Assessment method [2]
442981
0
Photographs will be taken pre and post Device application to assess for adverse events (i.e.: skin application site irritation, bleeding, bruising or swelling), and assessment of any device related adverse events and comparing inflammatory markers (i.e.: CRP results taken from a blood test) pre and post Device application. Additionally, any adverse events reported or observed by the study team, patient/guardian or treating clinicians will be recorded.
Query!
Timepoint [2]
442981
0
Photographs taken immediately prior to application and within 5 minutes of removal of the Nutromics Sensor Devices. Inflammatory markers will be tested at the 1- and 10-hour timepoints for each 24-hour observation period. Adverse events reported within 24 hours of observation by the study team, patient/guardian or treating clinicians.
Query!
Secondary outcome [3]
443896
0
Safety of vancomycin treatment
Query!
Assessment method [3]
443896
0
Collection of data the patient medical records regarding vancomycin treatment related adverse reactions
Query!
Timepoint [3]
443896
0
30 days post cessation of the course of therapy.
Query!
Secondary outcome [4]
442983
0
Understand perceptions of healthcare professionals (including doctors and nurses) of the utility and impact on workflows of using the device to inform vancomycin dosing decisions. This will be assessed as a composite outcome.
Query!
Assessment method [4]
442983
0
Survey that has been developed specifically for this study, regarding the human factors, perceptions of healthcare professionals, including prescribers, nurses and pharmacists on the utility and impact on workflow of using the Device (post data processing), and how such technology might inform vancomycin dosing decisions in ICU patients.
Query!
Timepoint [4]
442983
0
The survey will take place after the completion of part 1; once all 30-day post treatment outcomes have been collected.
Query!
Secondary outcome [5]
443897
0
Pharmacokinetics (AUC 12/24, Cmax, Tmax and T1/2) of vancomycin in interstitial fluid
Query!
Assessment method [5]
443897
0
Interstitial fluid
Query!
Timepoint [5]
443897
0
Interstitial fluid concentrations continuously measured by the Device over 24 hour period
Query!
Secondary outcome [6]
442982
0
Pharmacokinetics (AUC 12/24, Cmax, Tmax and T1/2) of vancomycin in plasma
Query!
Assessment method [6]
442982
0
Blood plasma samples
Query!
Timepoint [6]
442982
0
Blood taken: - prior to the administration of each vancomycin infusion, then at the end of the infusion and then at 1, 2, 3, 4, 6, 8 and 10-hours post-end of the infusion (if patient on intermittent vancomycin regimen), OR 2 hours after the syringe/infusion swap and 2 hours prior then next syringe/infusion swap (if patient on continuous vancomycin therapy).
Query!
Eligibility
Key inclusion criteria
Part 1:
• Age 18-80 years
• Hospitalised adults admitted to intensive care unit
• Prescribed vancomycin treatment administered intravenously (intermittent or continuous administration) by attending medical team irrespective of the duration of therapy
• Written informed consent (or of their authorised representative/guardian)
• Arterial or venous access
Part 2:
• Intensive care healthcare professionals, including prescribers (senior and junior), nurses and pharmacists, involved in the use of the Device.
• Written informed consent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Part 1:
• Participants who are currently receiving or have received any investigational drug/device within the last 10 days.
• Participants with a history of allergic reactions to metals, plastics and adhesives which, in the opinion of the Study Investigators, would increase the risk of having allergic reactions associated with Device.
• Participants with dermatological (or other) condition preventing application of Device.
• Participants who are pregnant or lactating.
Part 2:
• None
Query!
Study design
Purpose of the study
Diagnosis
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
All participants will continue to receive their standard care but have the Nutromics Sensor Device(s) applied and have additional blood draws. Blood is taken:
- prior to the administration of each vancomycin infusion, then at the end of the infusion and then at 1, 2, 3, 4, 6, 8 and 10-hours post-end of the infusion (if patient on intermittent vancomycin regimen), OR
- 2 hours after the syringe/infusion swap and 2 hours prior then next syringe/infusion swap (if patient on continuous vancomycin therapy).
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Part 1: The total number of participants is expected to be 40. The sample size is based on similar approaches used to compare bioanalytical methods, where 40-100 samples (i.e. AUC values) are suggested. Approximately 40 participants are required to provide 120 samples.
The vancomycin concentration-time profile will be plotted and the area under the concentration-time curve (AUC) over a dosing interval (12 or 24 hours) will be compared across the two matrices (interstitial fluid vs plasma). Additional pharmacokinetic parameters (e.g. peak concentration, time to peak concentration) will be determined and compared across the matrices. A mathematical model (physiological based pharmacokinetic model) will be developed to describe the pharmacokinetics of vancomycin in both plasma and interstitial fluid.
Descriptive statistics and correlation analysis will be used to characterise the relationship between vancomycin exposure based on continuous monitoring and efficacy and safety outcomes related to the course of vancomycin.
Part 2: Stakeholders involved in the use of the Device and care of ICU patients will be recruited. The total number of healthcare professionals (physicians, pharmacists and nurses) is expected to be 15-20.
De-identified surveys will be analysed to identify themes. Investigators will meet periodically throughout data collection to discuss survey responses and themes.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
24/03/2025
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
60
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
27417
0
Westmead Hospital - Westmead
Query!
Recruitment postcode(s) [1]
43530
0
2145 - Westmead
Query!
Funding & Sponsors
Funding source category [1]
318036
0
Commercial sector/Industry
Query!
Name [1]
318036
0
Nutromics Pty Ltd
Query!
Address [1]
318036
0
Query!
Country [1]
318036
0
Australia
Query!
Funding source category [2]
318035
0
Other
Query!
Name [2]
318035
0
Ramaciotti Health Investment Grant
Query!
Address [2]
318035
0
Query!
Country [2]
318035
0
Australia
Query!
Primary sponsor type
University
Query!
Name
The University of Sydney
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
320380
0
None
Query!
Name [1]
320380
0
Query!
Address [1]
320380
0
Query!
Country [1]
320380
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
316691
0
Western Sydney Local Health District Human Research Ethics Committee
Query!
Ethics committee address [1]
316691
0
https://www.wslhd.health.nsw.gov.au/Education-Portal/Research/ethics-governance
Query!
Ethics committee country [1]
316691
0
Australia
Query!
Date submitted for ethics approval [1]
316691
0
04/10/2024
Query!
Approval date [1]
316691
0
16/12/2024
Query!
Ethics approval number [1]
316691
0
Query!
Summary
Brief summary
The purpose of this study is to test the hypothesis that it is feasible and safe to use the Nutromics Sensor Device (investigational device; further called ‘Device’ in the protocol) to continuously monitor vancomycin concentrations in the interstitial fluid of intensive care unit (ICU) patients. This is a multi-site, mixed methods study consisting of a prospective observational study (Part 1) and survey with healthcare professionals (Part 2). The overall study duration is expected to be 18 months. Part 1 involves the application of two Devices over a period of 24 hours, and the comparison of the vancomycin concentrations measured by the device to those measured in plasma from blood samples. This 24 hour period of observation will be repeated on two occasions. These 24 hour periods of observation do not need to be sequential. In addition, assessment of Device safety will be determined. Associations between vancomycin concentrations measured by the Devices and treatment efficacy/safety up to 30 days post cessation of the course of therapy or post ICU discharge; whichever is sooner, will be determined from medical records. Part 2 involves the completion of a survey by stakeholders (physicians, pharmacists and nurses) involved in the use of the Device and thematic analysis of responses.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
138682
0
A/Prof Sophie Stocker
Query!
Address
138682
0
Rm No S303, Building No A15, The University of Sydney,NSW 2006
Query!
Country
138682
0
Australia
Query!
Phone
138682
0
+61 427 490 796
Query!
Fax
138682
0
Query!
Email
138682
0
[email protected]
Query!
Contact person for public queries
Name
138683
0
Sophie Stocker
Query!
Address
138683
0
Rm No S303, Building No A15, The University of Sydney,NSW 2006
Query!
Country
138683
0
Australia
Query!
Phone
138683
0
+61 427 490 796
Query!
Fax
138683
0
Query!
Email
138683
0
[email protected]
Query!
Contact person for scientific queries
Name
138684
0
Sophie Stocker
Query!
Address
138684
0
Rm No S303, Building No A15, The University of Sydney,NSW 2006
Query!
Country
138684
0
Australia
Query!
Phone
138684
0
+61 427 490 796
Query!
Fax
138684
0
Query!
Email
138684
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
No
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF